Aurobindo's US operations get growth boost; stock up 9% on Sandoz deal

Attractive valuations, large portfolio add to growth pipeline, keep leverage ratios moderate

Aurobindo Pharma, one of the largest vertically-integrated pharmaceutical companies in the country, continues with it acquisition-led growth strategy, announcing yet another buy in the US. 

It is acquiring commercial operations and three manufacturing facilities from Sandoz Inc, which will help it become the second largest generic player in the US by number of prescriptions. 

The acquired portfolio will include oral solids (70 per cent) and dermatology products (30 per cent). 

The Street gave a thumbs up to the deal, with the stock gaining over nine per cent on Thursday. 

The deal, valued at about one-time sales, will also make Aurobindo